Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
Details of the poster presentations are as follows:
Title: Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGF-β inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (cSCC)
Published Abstract #: CT034
Session Category: Clinical Trials
Session Title: Phase 0 and Phase I Clinical Trials
Session Date and Time: 4/28/2025 9:00 a.m. CT
Location: McCormick Place Convention Center, Poster Section 49
This presentation will highlight data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC patients.
Title: Dual blockade of EGFR and TGF-β with ficerafusp alfa has the potential to overcome resistance mechanisms in 1L R/M HNSCC in combination with Pembrolizumab
Published Abstract #: 3284
Session Category: Clinical Research
Session Title: Modifiers of the Tumor Microenvironment
Session Date and Time: 4/28/2025 2:00 p.m. CT
Location: McCormick Place Convention Center, Poster Section 30
This presentation will highlight a translational medicine biomarker dataset that provides insights into the effects of targeted inhibition of TGF-β with ficerafusp alfa.
Title: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors
Published Abstract #: 4434
Session Category: Experimental and Molecular Therapies
Session Title: Reversal of Drug Resistance
Session Date and Time: 4/29/2025 9:00 a.m. CT
Location: McCormick Place Convention Center, Poster Section 23
This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.
Following the meeting, the poster presentations will be available on Bicara's website at www.bicara.com.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara's lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Bicara's preclinical studies and presentation of results, the clinical development of ficerafusp alfa and presentation of data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC, clinical development of ficerafusp alfa in combination with pembrolizumab, the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy and tolerability. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct and enrollment of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials and regulatory developments in the United States and foreign countries, whether Bicara's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara's filings with the Securities and Exchange Commission (SEC), including Bicara's Quarterly Report on Form 10-Q for the period ended September 30, 2024, as well as any subsequent filings that Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara's views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Contacts
Investors
Rachel Frank
Media
Dan Budwick
1AB
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
CoreWeave reportedly a key player in Google-OpenAI partnership
-- CoreWeave is set to provide computing capacity to Google (NASDAQ:GOOGL) Cloud as part of Google's newly formed partnership with OpenAI, according to a Reuters report on Wednesday. The arrangement involves CoreWeave supplying cloud computing services built on Nvidia (NASDAQ:NVDA)'s graphics processing units to Google's cloud unit. Google will then sell this computing capacity to OpenAI to help meet the growing demand for services such as ChatGPT. In addition to CoreWeave's resources, Google will also provide some of its own computing resources to OpenAI. The deal demonstrates how the high demand for AI computing resources is creating new business alliances, even among the industry's fiercest rivals. Related articles CoreWeave reportedly a key player in Google-OpenAI partnership Dana stock surges amid $2.7 billion Off-Highway business sale to Allison Oklo and Centrus Energy stocks jump after DoD nuclear reactor award Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
31 minutes ago
- Yahoo
Dave & Buster's (PLAY) Stock Trades Up, Here Is Why
Shares of arcade company Dave & Buster's (NASDAQ:PLAY) jumped 14.8% in the afternoon session after the company reported first-quarter 2025 results and provided encouraging updates on sales trends, as revenue came in line with expectations. The company noted improved momentum following the reintroduction of the Eat & Play combo, adjustments to menu pricing, and changes to the incentive structure for store managers. Additionally, free cash flow turned positive, which is a significant boost as management attempts to turn around the business. Given that markets are forward-looking, the stock's reaction suggests investors were able to look past the bottom line weakness during the quarter as operating profits and earnings fell short of Wall Street's estimates. The shares closed the day at $30.46, up 17.7% from previous close. Is now the time to buy Dave & Buster's? Access our full analysis report here, it's free. Dave & Buster's shares are extremely volatile and have had 42 moves greater than 5% over the last year. But moves this big are rare even for Dave & Buster's and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 15 days ago when the stock gained 5.5% on the news that the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. Dave & Buster's is down 0.3% since the beginning of the year, and at $30.20 per share, it is trading 40% below its 52-week high of $50.35 from June 2024. Investors who bought $1,000 worth of Dave & Buster's shares 5 years ago would now be looking at an investment worth $2,064. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
34 minutes ago
- CNBC
Stock futures are little changed after S&P 500 ends three-day win streak: Live updates
Traders wait for Voyager Technologies to begin trading during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., June 11, 2025. Brendan McDermid | Reuters Stock futures were relatively unchanged on Wednesday after the S&P 500 saw its first negative session in four. S&P 500 futures traded down by 0.1%, along with Nasdaq 100 futures . Futures tied to the Dow Jones Industrial Average dropped 44 points, or 0.1%. In extended trading, shares of Oracle surged more than 7% after its fiscal fourth-quarter results beat on the top and bottom lines. The company also indicated more cloud growth ahead, saying in a statement that cloud infrastructure revenue will rise by more than 70% in fiscal 2026, up from a 50% growth rate in the prior fiscal year. Wednesday marked a losing session on Wall Street, with the S&P 500 snapping its three-day win streak, as did the Nasdaq Composite . But the moves were slight. The broad market index fell about 0.3%, while tech-heavy Nasdaq dropped 0.5%. The Dow Jones Industrial Average was flat. While the day's losses put the S&P 500 a bit further away from reaching a new record high, the index is also still just more than 2% below its late February record. Those moves come after consumer prices rose less than expected in May, as the consumer price index increased 0.1% for the month. That's less than the Dow Jones forecast for 0.2%. Core CPI, which excludes food and energy prices, also increased less than expected. "I don't think the market has a lot of faith that we're not going to see at least a little bit higher inflation," Scott Wren, senior global market strategist at Wells Fargo, told CNBC's "Closing Bell" Wednesday. "With all the things going on, the economy slowing, earnings growth likely to slow, lots of trade negotiations to still work through, is there really a good reason to take a run at the record high? I don't know about that. It makes a lot of sense to me that we'd be choppy and maybe see a little downside here." Investors are now looking ahead to May's reading of the producer price index, due out at 8:30 a.m. ET on Thursday. Economists polled by Dow Jones are expecting the index to show a gain of 0.2% for the period. Subtracting out food and energy, core PPI is expected to show growth of 0.3% on the month. The Street is also waiting for more developments on trade, especially between the U.S. and China, as talks between the two countries have been a focal point this week. While officials reached an agreement in London, the deal still awaits approval from U.S. President Donald Trump and Chinese President Xi Jinping. Trump said in a post on Truth Social earlier Wednesday that "WE ARE GETTING A TOTAL OF 55% TARIFFS, CHINA IS GETTING 10%." However, Commerce Secretary Howard Lutnick later said that U.S. levies on goods from China won't change from their current levels. Rising tensions between the U.S. and Iran will also be in focus. U.S. crude oil futures jumped more than 4% on Wednesday after Trump expressed doubt that the two countries could reach a nuclear deal.
